



## Project List

Project Name	<b>Building 156 Pilot Plant</b>
Owner	<b>Pfizer</b>
Architect	
Date of Completion	5/2001
Project Issues	Potent compound, cross contamination, personnel protection, regulatory issues
Scope	Retrofit of existing pilot plant for API production @ 30 ngram/M <sup>3</sup> /shift. Options, recommendations, design, testing, surrogate testing and training.
Project Name	<b>Pilot Plant Annex</b>
Owner	<b>Pfizer</b>
Architect	
Date of Completion	9/2001
Project Issues	Potent compound, Personnel protection, API, new facility
Scope	Review of milling options
Project Name	<b>SEG80 Equipment Containment Design</b>
Owner	<b>Pfizer</b>
Architect	
Date of Completion	11/2000
Project Issues	Potent compound, cross contamination, retrofit, API
Scope	Options and recommendations for reactor charging, drying off load and subdivision
Project Name	<b>Wet Chemistry Isolator</b>
Owner	<b>Pfizer</b>
Architect	CE&IC
Date of Completion	2/2001
Project Issues	Potent compound, API, Cytotoxic, cross contamination, personnel protection, new facility
Scope	Design review, client representative, surrogate testing and training



Project Name	<b>Miscellaneous Projects for Sanofi-Synthelabo</b>
Owner	<b>Sanofi-Synthelabo</b>
Architect	
Date of Completion	On going
Project Issues	Potent compounds, Aseptic, OSD, Aseptic/sterile fill finish, API, Cytotoxic, cross contamination, personnel protection, retrofit and new facilities
Scope	All containment issues on site including advice, options and recommendations, ergonomics, design management, IQ, OQ, Installation, maintenance and training
Project Name	<b>Dust Collection System</b>
Owner	<b>AstraZeneca</b>
Architect	
Date of Completion	2/2000
Project Issues	Potent compounds, OSD, cross contamination, personnel protection, retrofit facilities
Scope	Options and recommendations for coating dust collection
Project Name	<b>Filter Dryer Isolator</b>
Owner	<b>Organichem</b>
Architect	
Date of Completion	5/2002
Project Issues	Potent compounds, API, cytotoxics, cross contamination, personnel protection, new facility
Scope	Options, recommendations, surrogate testing and training for filter drying subdivision and reactor charging
Project Name	<b>Low Humidity Isolators</b>
Owner	<b>Wyeth</b>
Architect	
Date of Completion	9/2001
Project Issues	Potent compounds, cross contamination, personnel protection
Scope	Options and recommendations, ergonomics for reference filling



Project Name **Ergonomic Review, Bid Review**  
Owner **Merck**  
Architect Foster Wheeler  
Date of Completion 12/2001  
Project Issues Potent compounds, API, cross contamination, personnel protection, new facility  
Scope Review engineer's and vendor's design, redesign, ergonomic review and design

Project Name **Building 250, Bio-processing Facility**  
Owner **Wyeth Pearl River, NY**  
Architect TKLP/PFI  
Date of Completion 2004  
Project Issues Potent compounds, aseptic, API, aseptic/sterile fill finish, cytotoxic, cross contamination, personnel protection, regulatory issues, new facility  
Scope Options and recommendations, design and support, ergonomic modeling, surrogate testing

Project Name **Pipeline OSD**  
Owner **Wyeth Guayama Puerto Rico**  
Architect  
Date of Completion 11/2003  
Project Issues Potent compounds, OSD, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities  
Scope Options and recommendations, ergonomics, design, bid, testing and training for OSD retrofit including subdivision, granulation, fluid bed drying, blending, tableting and coating

Project Name **Contained Potent Aseptic Filling Line with Lyophilization**  
Owner **Seattle Genetics**  
Architect  
Date of Completion 7/2002  
Project Issues Potent compounds, aseptic, aseptic/sterile fill finish, cytotoxic, cross contamination, personnel protection, regulatory issues, new facility  
Scope Options and recommendations with cost estimate for potent clinical trial facility



Project Name **Option Report for Handling Potent Compounds for OSD**  
Owner **Schering Plough**  
Architect  
Date of Completion 9/2002  
Project Issues Potent compounds, OSD, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities  
Scope Options and recommendations for safe handling of OSD products

Project Name **Miscellaneous Project**  
Owner **Bristol Myers Squibb, Syracuse, NY**  
Architect  
Date of Completion On going  
Project Issues Potent compounds, API, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities  
Scope Options, recommendations, ergonomics and bid documents

Project Name **Laboratory Containment**  
Owner **Bristol Myers Squibb**  
Architect  
Date of Completion 2003  
Project Issues Potent compounds, API, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities  
Scope Options and recommendations including cost estimate

Project Name **Options Report for Aerosol Formulate and Filling KOS/Aeropharm**  
Owner  
Architect  
Date of Completion 8/2002  
Project Issues Novel drug delivery, cross contamination, retrofit facilities  
Scope Options and recommendations and design for contained nasal insulin

Project Name **Potent Facility for Roxanne Laboratories**  
Owner **Boehringer Ingelheim**  
Architect AMEC  
Date of Completion 2003  
Project Issues Potent compounds, OSD, cytotoxic, cross contamination, personnel protection, regulatory issues, new facility  
Scope Options and recommendations with budget costs



Project Name	<b>Miscellaneous Projects</b>
Owner	<b>Ben Venue Laboratories</b>
Architect	
Date of Completion	In progress
Project Issues	Potent compounds, aseptic, aseptic/sterile fill finish, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities
Scope	Review of all processes, options and recommendations
Project Name	<b>Options Report</b>
Owner	<b>Wyeth Rouses Point</b>
Architect	
Date of Completion	2002
Project Issues	Potent compounds, OSD, cross contamination, personnel protection, regulatory issues, retrofit facilities
Scope	Options and recommendations report
Project Name	<b>Options Report</b>
Owner	<b>Genpharm</b>
Architect	
Date of Completion	3/2003
Project Issues	Potent compounds, OSD, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities
Scope	Options and recommendations for safe handling of OSD products
Project Name	<b>PK 150 Project</b>
Owner	<b>Wyeth Rouses Point</b>
Architect	
Date of Completion	2/2004
Project Issues	Potent compounds, OSD, cross contamination, personnel protection, regulatory issues, new facilities within existing warehouse for 150 nanogram OEL material for unloading, milling, blending and packing
Scope	Options and recommendations, system design and execution, bid documentation, bid review, vendor administration, FAT, SAT, surrogate testing, training



Project Name	<b>Concept Design/Options Report/Bid Documentation</b>
Owner	<b>Novex Pharma</b>
Architect	SMA Biometrics
Date of Completion	12/2003
Percentage of Worked Performed by Us	
Project Issues	Cross contamination, regulatory issues
Scope	Contained parenteral production of ophthalmics and parenterals, options and recommendation including budgetary prices, URS development, bid support
Project Name	<b>Gap Analysis for Parenteral Facility</b>
Owner	<b>Wyeth Carolina</b>
Architect	
Date of Completion	2003
Project Issues	Potent compounds, aseptic, aseptic/sterile fill finish, cytotoxic, cross contamination, personnel protection, regulatory issues, retrofit facilities
Scope	Review of all containment issues to handle potent compounds, options and recommendations
Project Name	<b>Review of P4 Upgrade</b>
Owner	<b>Swords Laboratories Bristol Myers Squibb</b>
Architect	Project Management/ Foster Wheeler
Date of Completion	12/2002
Project Issues	Potent compounds, aseptic, aseptic/sterile fill finish, cross contamination, personnel protection, regulatory issues, new facility
Scope	Review of documentation
Project Name	<b>Parenteral Manufacturing</b>
Owner	<b>Bristol Myers Squibb</b>
Architect	
Date of Completion	On going
Project Issues	Potent compounds, aseptic/sterile fill finish, contamination control, personnel protection, regulatory issues, new facility
Scope	Attend vendor's presentations, define scope, options and recommendations report for 6 filling lines and multiple lyophilizers with auto loading



Project Name **CSO Facility**  
Owner **Bristol Myers Squibb New Brunswick**  
Architect **IPS**  
Date of Completion **On going**  
Project Issues **Potent compounds, aseptic/sterile fill finish, OSD, contamination control, personnel protection, retrofit facilities**  
Scope **Options and recommendations with design to  $\pm$  25% budget and budget for capital approval for a new clinical parenteral facility**

Project Name **Parenteral Facility Review**  
Owner  
Architect **JGC Corporation**  
Date of Completion **1/2003**  
Project Issues **Potent compounds, aseptic/sterile fill finish, contamination control, personnel protection, regulatory issues, new facilities**  
Scope **Review documents, comment and make recommendations**

Project Name **Containment Options for B97 Tech Center/B98 and B96**  
Owner **Tyco Healthcare/Mallinckrodt**  
Architect  
Date of Completion **9/2003**  
Project Issues **Potent compounds, contamination control, personnel protection, regulatory issues**  
Scope **Options and recommendations report**

Project Name **Evaluation for Processing Hormone Product**  
Owner **Able Laboratories**  
Architect  
Date of Completion **9/2003**  
Project Issues **Potent compounds, contamination control, personnel protection, regulatory issues**  
Scope **Review process and documents, comment and make recommendations, provided training video**



**Project Name**                    **Pilot and Development Scale Containment**  
**Owner**                            **Cambrex, North Brunswick, NJ**  
**Architect**  
**Date of Completion**        2/2004  
**Project Issues**                Potent compounds, contamination control, personnel protection, regulatory issues, new facilities  
**Scope**                            Options and recommendations report, ergonomic evaluation, bid documentation, bid review, vendor administration, training

**Project Name**                    **N2 ODPF Retrofit Project**  
**Owner**                            **Chiron Corporation**  
**Architect**  
**Date of Completion**        9/2003  
**Project Issues**                Potent compounds, aseptic/sterile fill finish, contamination control, personnel protection, regulatory issues, retrofit facilities  
**Scope**                            Options and recommendations report with  $\pm 20\%$  budgetary costing

**Project Name**                    **Containment Consulting**  
**Owner**                            **Dr. Reddy's Laboratories**  
**Architect**  
**Date of Completion**        12/2003  
**Project Issues**                Potent compounds, aseptic/sterile fill finish, contamination control, personnel protection, regulatory issues, new facilities  
**Scope**                            Review documents, comment and make recommendations

**Project Name**                    **Options Report**  
**Owner**                            **Apotex**  
**Architect**  
**Date of Completion**        6/2003  
**Project Issues**                Potent compounds, contamination control, personnel protection, regulatory issues for subdivision  
**Scope**                            Options and recommendations report



Project Name	<b>Dust Reduction</b>
Owner	<b>Wyeth</b>
Architect	
Date of Completion	7/2003
Project Issues	Reduction of hazardous waste from dust collection system, contamination control, personnel protection, regulatory issues
Scope	Review process, comment and make recommendations
Project Name	<b>Campus Expansion</b>
Owner	<b>Chiron Corporation</b>
Architect	CRB
Date of Completion	In process
Project Issues	Potent compounds, aseptic/sterile fill finish, contamination control, personnel protection, regulatory issues, new facilities for development and clinical scale API, OSD and parenteral products
Scope	Options and recommendations